CRISPR Therapeutics (NASDAQ:CRSP) Trading 5.8% Higher

CRISPR Therapeutics AG (NASDAQ:CRSPGet Free Report) traded up 5.8% during mid-day trading on Monday . The stock traded as high as $64.61 and last traded at $64.57. 1,325,700 shares traded hands during mid-day trading, a decline of 34% from the average session volume of 2,021,186 shares. The stock had previously closed at $61.01.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Mizuho reiterated a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, December 8th. Royal Bank of Canada increased their target price on CRISPR Therapeutics from $50.00 to $57.00 and gave the company a “sector perform” rating in a report on Monday, December 11th. Morgan Stanley dropped their target price on CRISPR Therapeutics from $43.00 to $42.00 and set an “underweight” rating on the stock in a report on Monday, November 13th. Cantor Fitzgerald lowered CRISPR Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, October 17th. Finally, TD Cowen lowered CRISPR Therapeutics from a “market perform” rating to an “underperform” rating and set a $30.00 target price on the stock. in a report on Monday, December 11th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $68.39.

View Our Latest Stock Analysis on CRSP

CRISPR Therapeutics Trading Down 2.0 %

The firm’s 50 day moving average price is $64.73 and its two-hundred day moving average price is $54.83.

CRISPR Therapeutics (NASDAQ:CRSPGet Free Report) last announced its earnings results on Monday, November 6th. The company reported ($1.41) earnings per share for the quarter, topping the consensus estimate of ($2.04) by $0.63. CRISPR Therapeutics had a negative net margin of 240.84% and a negative return on equity of 19.10%. During the same quarter in the prior year, the business earned ($2.24) earnings per share. Research analysts expect that CRISPR Therapeutics AG will post -3.11 EPS for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $62.50, for a total value of $1,250,000.00. Following the completion of the sale, the chief executive officer now owns 187,377 shares in the company, valued at $11,711,062.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.10% of the stock is owned by insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CRSP. Fairfield Bush & CO. acquired a new stake in shares of CRISPR Therapeutics during the 1st quarter valued at approximately $90,000. Bank of New York Mellon Corp lifted its position in shares of CRISPR Therapeutics by 40.7% during the 1st quarter. Bank of New York Mellon Corp now owns 91,062 shares of the company’s stock valued at $5,716,000 after acquiring an additional 26,358 shares during the period. US Bancorp DE lifted its position in shares of CRISPR Therapeutics by 10.0% during the 1st quarter. US Bancorp DE now owns 9,526 shares of the company’s stock valued at $598,000 after acquiring an additional 866 shares during the period. BlackRock Inc. lifted its position in shares of CRISPR Therapeutics by 79.2% during the 1st quarter. BlackRock Inc. now owns 2,278,774 shares of the company’s stock valued at $143,038,000 after acquiring an additional 1,007,246 shares during the period. Finally, Cibc World Market Inc. lifted its position in shares of CRISPR Therapeutics by 49.3% during the 1st quarter. Cibc World Market Inc. now owns 8,354 shares of the company’s stock valued at $524,000 after acquiring an additional 2,760 shares during the period. Institutional investors and hedge funds own 68.20% of the company’s stock.

CRISPR Therapeutics Company Profile

(Get Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Further Reading

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.